Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: A controlled pilot study

Infection

Volumn 40, Issue 1, 2012, Pages 69-75

  Bonora, S ^a   Calcagno, A ^a,b   Cometto, C ^a   Fontana, S ^a   Aguilar, D ^a   D'Avolio, A ^a   Gonzalez De Requena, D ^a   Maiello, A ^a   Dal Conte, I ^a   Lucchini, A ^a   Di Perri, G ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b AMEDEO DI SAVOIA HOSPITAL   (Italy)

Author keywords

Advanced na ve; Enfuvirtide; HIV; Immunological recovery

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADD ON THERAPY; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4 LYMPHOCYTE PERCENTAGE; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PILOT STUDY; SHORT COURSE THERAPY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; ITALY; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PILOT PROJECTS; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 84857788884     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-011-0223-4     Document Type: Article

References (28)

1. MM Kitahata SJ Gange AG Abraham, et al. 2009 Effect of early versus deferred antiretroviral therapy for HIV on survival N Engl J Med 360 1815 1826 19339714 10.1056/NEJMoa0807252 1:CAS:528:DC%2BD1MXlsVGmtrY%3D
2. When To Start Consortium JA Sterne M May, et al. 2009 Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies Lancet 373 1352 1363 19361855 10.1016/S0140-6736(09)60612-7
3. ML Petersen MJ van der Laan S Napravnik, et al. 2008 Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification AIDS 22 2097 2106 18832873 10.1097/QAD.0b013e32830f97e2
4. A Adler S Mounier-Jack RJ Coker 2009 Late diagnosis of HIV in Europe: definitional and public health challenges AIDS Care 21 284 293 19031304 10.1080/09540120802183537 1:STN:280:DC%2BD1M3gtFSntw%3D%3D
5. M Egger M May G Chêne, et al. 2002 Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies Lancet 360 119 129 12126821 10.1016/S0140-6736(02)09411- 4 (Erratum in: Lancet 2002 Oct 12;360(9340):1178) (Pubitemid 34786200)
6. B Grinsztejn VG Veloso RK Friedman, et al. 2009 Early mortality and cause of deaths in patients using HAART in Brazil and the United States AIDS 23 2107 2114 19770698 10.1097/QAD.0b013e32832ec494
7. CF Kelley CM Kitchen PW Hunt, et al. 2009 Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment Clin Infect Dis 48 787 794 19193107 10.1086/597093
8. SD Lawn L Myer LG Bekker, et al. 2006 CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa BMC Infect Dis 6 59 16551345 10.1186/1471-2334-6-59
9. GR Kaufmann H Furrer B Ledergerber, et al. 2005 Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy Clin Infect Dis 41 361 372 16007534 10.1086/431484 (Pubitemid 41022115)
10. CA Sabin CJ Smith H Gumley, et al. 2004 Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy AIDS 18 2145 2151 15577647 10.1097/00002030-200411050-00006 (Pubitemid 39463679)
11. M Wolbers HC Bucher H Furrer, et al. 2008 Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study HIV Med 9 397 405 18410354 10.1111/j.1468-1293.2008.00566.x 1:CAS:528:DC%2BD1cXhtVSkurjM (Pubitemid 352015643)
12. A Grigoryan HI Hall T Durant, et al. 2009 Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996-2004 PLoS One 4 e4445 19214229 10.1371/journal.pone.0004445
13. E Poveda B Rodés JL Labernardière, et al. 2004 Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure J Med Virol 74 21 28 15258964 10.1002/jmv.20141 1:CAS:528:DC%2BD2cXntFGltLo%3D (Pubitemid 38988855)
14. L Pérez-Alvarez R Carmona A Ocampo, et al. 2006 Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1 J Med Virol 78 141 147 16372284 10.1002/jmv.20520 (Pubitemid 43132556)
15. S Aquaro R D'Arrigo V Svicher, et al. 2006 Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment J Antimicrob Chemother 58 714 722 16891628 10.1093/jac/dkl306 1:CAS:528:DC%2BD28Xps1yjsL0%3D (Pubitemid 44390943)
16. TE Melby M Despirito RA Demasi, et al. 2007 Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy AIDS 21 2537 2539 18025893 10.1097/QAD.0b013e3282f12362 1:CAS:528:DC%2BD2sXhtlWjtL3K (Pubitemid 350145188)
17. JP Viard C Fagard ML Chaix, et al. 2009 Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients AIDS 23 1383 1388 19461505 10.1097/QAD.0b013e32832cdc26 1:CAS:528:DC%2BD1MXnsl2gsLk%3D
18. A Bourgarit C Lascoux P Palmer, et al. 2006 First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases AIDS 20 471 473 16439888 10.1097/01.aids.0000199826. 72359.9d
19. J Moltó L Ruiz M Valle, et al. 2006 Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients Antivir Ther 11 47 51 16518959
20. A D'Avolio L Baietto M Siccardi, et al. 2008 An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients Ther Drug Monit 30 662 669 18824956 10.1097/FTD.0b013e318189596d
21. A D'Avolio M Sciandra DG de Requena, et al. 2006 An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients Ther Drug Monit 28 110 115 16418704 10.1097/01.ftd. 0000179421.25337.62 (Pubitemid 44391704)
22. A Zolopa J Andersen W Powderly, et al. 2009 Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial PLoS One 4 e5575 19440326 10.1371/journal.pone.0005575
23. Joly V, Fagard C, Descamps D, et al. Intensification of HAART through the addition of enfuvirtide (ENF) in naïve HIV-infected patients with severe immunosuppression does not improve immunological response: results of a prospective randomised multicenter trial (APOLLO -ANRS 130). In: 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010), San Francisco, CA, 16-19 February 2010. Abstract K-117, PB 282. Available online at: http://retroconference.org/2010/PDFs/282.pdf
24. J Sierra-Madero G Di Perri R Wood, et al. 2010 Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study HIV Clin Trials 11 125 132 20736149 10.1310/hct1103-125 1:CAS:528:DC%2BC3MXkslWlsro%3D
25. Carsenti-Dellamonica H, Durant J, Ticchioni M, et al. Enfuvirtide therapy increases naïve and central memory CD4 T cells, decreases the level of immune activation and apoptosis. In: 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008), Boston, MA, 3-6 February 2008. Abstract # A153, Poster board #446, Session #75. Available online at: http:// retroconference.org/2008/PDFs/446.pdf
26. J Barretina J Blanco A Bonjoch, et al. 2004 Immunological and virological study of enfuvirtide-treated HIV-positive patients AIDS 18 1673 1682 15280778 10.1097/01.aids.0000131350.22032.b5 1:CAS:528:DC%2BD2cXlvF2ksrc%3D (Pubitemid 39095784)
27. H Garg A Joshi EO Freed, et al. 2007 Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion J Biol Chem 282 16899 16906 17416587 10.1074/jbc.M701701200 1:CAS:528:DC%2BD2sXmt1agsL4%3D (Pubitemid 47093247)
28. VC Marconi G Grandits JF Okulicz, et al. 2011 Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS PLoS One 6 e17956 21625477 10.1371/journal.pone. 0017956 1:CAS:528:DC%2BC3MXms1KmsLw%3D